OBJECTIVE: b-Adrenoceptor-mediated whole-body lipolysis is impaired in obesity. This study investigated whether local adipocyte b-adrenergic sensitivity and changes in nutritive blood flow in subcutaneous abdominal adipose tissue contribute to this impaired response. METHODS: Three microdialysis probes were placed in the subcutaneous abdominal adipose tissue of eight obese and nine lean men. Each probe was perfused with either 0.1, 1 and 10 mM isoprenaline; 1, 10 and 100 mM dobutamine or 1, 10 and 100 mM salbutamol, each dose for 45 min. RESULTS: At baseline, interstitial glycerol concentrations and ethanol out/in ratios were comparable between groups. During nonselective b-, b 1 -and b 2 -adrenergic stimulation, interstitial glycerol concentrations increased and ethanol out/in ratios decreased similarly in obese and lean men. CONCLUSION: The lipolytic and nutritive blood flow response to b 1 -b 2 -and nonselective b-adrenergic stimulation in situ is comparable in lean and obese male subjects. The present data suggest that a blunted b-adrenergic sensitivity of the fat cell and an impaired local nutritive blood flow response do not contribute to the previously reported diminished whole-body badrenoceptor-mediated lipolytic response in obese males.
Introduction
Obesity is associated with a blunted lipolytic response during increased sympathetic nervous system activity. Literature shows that whole-body lipolysis is impaired in obese subjects during i.v. epinephrine 1, 2 or isoprenaline (nonselective badrenoceptor agonist) 3 infusion. Furthermore, glycerol and nonesterified fatty acids (NEFA) release from abdominal adipose tissue is blunted in obese females during epinephrine infusion. 4 In an earlier study, we showed that this blunted b-adrenoceptor-mediated lipolytic response only occurs during selective b 2 -adrenergic stimulation, whereas b 1 -adrenoceptor-mediated increases in lipolysis are similar in obese and lean men. 5 Several mechanisms may be responsible for the impaired whole-body b-adrenoceptor-mediated lipolytic response. On the one side, adipocyte b-adrenergic sensitivity for lipolysis might be diminished. In vitro studies show that glycerol release is reduced in subcutaneous abdominal fat cells from obese women after incubation with isoprenaline or terbutaline (b 2 -adrenoceptor agonist), whereas glycerol release is similar in fat cells from normal weight and overweight women after incubation with dobutamine (b 1 -adrenoceptor agonist). 6 On the other hand, the release of glycerol from the interstitial fluid into the systemic circulation may be reduced because of a diminished b-adrenoceptor-mediated adipose tissue blood flow response. Adipose tissue blood flow, as measured by the 133 xenon-clearance technique, is significantly lower in obese compared to lean subjects, both at rest [7] [8] [9] [10] [11] and during i.v. epinephrine 4, 12 and isoprenaline infusion. 8 The aim of the present study was to investigate subcutaneous adipose tissue lipolysis during local administration of b-agonists through a microdialysis probe to differentiate between local tissue events and systemic blood flow effects. Local adipose tissue lipolysis was determined by the continuous dialysis of glycerol in the extracellular fluid of abdominal subcutaneous adipose tissue. Local nutritive blood flow was determined by means of the ethanol dilution technique. [13] [14] [15] [16] .
Subjects and methods

Subjects
Eight obese and nine lean male volunteers participated in this study. Body density was determined by hydrostatic weighing with simultaneous lung volume measurement (Volugraph 2000, Mijnhardt, Bunnik, The Netherlands). Body composition was calculated according to the equation of Siri. 17 All subjects were in good health as assessed by medical history and physical examination. Furthermore, both obese and lean subjects spent no more than 2 h a week in organized sports activities. The study protocol was reviewed and approved by the Ethics Committee of Maastricht University, and all subjects gave informed consent before participating in the study.
Microdialysis experiments
All subjects were studied in the supine position after an overnight fast. They came to the laboratory by car or by bus. On arrival, three microdialysis probes (CMA 60, CMA Microdialysis, Solna, Sweden) were inserted percutaneously in subcutaneous abdominal adipose tissue. The skin was anesthetized by means of a crème containing lidocaine (25 mg/g) and prolocaine (25 mg/g) (Emla, Astra Pharmaceutica, Zoetermeer, The Netherlands). Probes were placed 5-8 cm left or right from the umbilicus and the distance between probes was at least 3 cm. Probes consisted of a dialysis tubing (30 Â 0.6 mm 2 , 20 kDa cutoff) glued to the end of a double lumen polyurethane canula. The perfusion solvent entered the probe through the inner canula, passed down to the tip of the probe, streamed upwards in the space between the inner canula and the outer dialysis membrane and left the probe through the outer canula via a side arm, from which it was collected.
Study design
After insertion, all probes were perfused with Ringer solution (147 mM sodium, 4 mM potassium, 2.25 mM calcium and 156 mM chloride) supplemented with 50 mM ethanol at a flow rate of 0.5 ml/min for 20 min before the start of the experiment. During the first part of the experiment, the real interstitial glycerol concentration was determined by means of the zero flow method. 18 Microdialysate was collected in two 20-min fractions at a flow rate of 0.5 ml/min and in three 10-min fractions at flow rates of 1, 2.5 and 5 ml/min. During the second part of the experiment, probes were perfused with increasing concentrations of different nonselective and selective b-adrenoceptor agonists at a flow rate of 5 ml/min. During each b-adrenoceptor agonist infusion period, one 15-min dialysate collection fraction was followed by three 10-min fractions. In all samples collected at flow rates of 0.5, 1 and 2.5 ml/min, dialysate glycerol concentrations were measured. In all other samples, both dialysate glycerol and ethanol concentrations were measured. Ethanol was determined both in the ingoing and outgoing perfusion solvent to asses the ethanol out/in ratio as indicator for nutritive blood flow (ethanol escape technique).
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Zero flow method During the first part of the experiment, the real interstitial glycerol concentration was determined by means of the zero flow method. 18 Therefore, probes were perfused at a flow rate of 0.5 ml/min for 40 min and at consecutive flow rates of 1, 2.5 and 5 ml/min for 30 min. Dialysate glycerol concentrations were log transformed and plotted against perfusion rates. Linear regression analysis was used to calculate the glycerol concentration at zero flow rate, corresponding to the real interstitial glycerol concentration. The ratio between the dialysate glycerol concentration at 5 ml/min and the calculated interstitial glycerol concentration represented the in vivo recovery rate of the probe.
b-Adrenoceptor agonists
During the second part of the experiment, each probe was perfused with a nonselective or selective b-adrenoceptor agonist to determine changes in lipolysis and blood flow. The calibration period with a flow rate of 5 ml/min was used as baseline measurement. Then one probe was perfused with 0.1, 1 and 10 mM isoprenaline to stimulate all b-adrenoceptor subtypes, the second probe was perfused with 1, 10 and 100 mM dobutamine to stimulate b 1 -adrenoceptors and the third probe was perfused with 1, 10 and 100 mM salbutamol to stimulate b 2 -adrenoceptors. Each dose of agonist was given for 45 min at a flow rate of 5 ml/min.
Analytical methods
Glycerol and ethanol concentrations in the dialysate were determined on a Cobas Fara centrifugal analyzer (Roche Diagnostica, Basel, Switzerland). Glycerol concentration was measured fluorimetrically using a standard glycerol kit (Boehringer, Mannheim, Germany), but with adapted concentrations of NADH, enzymes and buffer to achieve accurate fluorimetric detection. Ethanol concentration was measured spectrophotometrically at 340 nm using a standard ethanol kit (176290, Boehringer, Mannheim, Germany).
Data analysis
All data are presented as mean7standard error of the mean (s.e.m. 
Results
Physical characteristics of the subjects are summarized in Table 1 . By selection, obese men had a significantly higher body mass index, body fat %, fat-free mass and waist-hip ratio. However, groups were of similar height and age. Baseline interstitial glycerol concentrations were similar in all probes in obese and lean men (before nonselective 
Discussion
Obesity has been reported to be associated with an impaired lipolytic response during intravenous catecholamine infusion or b-adrenergic stimulation. [1] [2] [3] [4] This may be explained, on one hand, by an impaired b-adrenergic sensitivity of the fat cell, since in vitro studies have shown that glycerol release from subcutaneous adipocytes may be impaired in obese women after incubation with a b-or b 2 -agonist. 6 On the other hand, the release of glycerol from the interstitial fluid into the systemic circulation may be reduced because of a lowered adipose tissue blood flow response, as measured by xenon-clearance technique. 4, 8, 12 Local nutritive blood flow, as assessed by the microdialysis technique by determining the ethanol out/in ratio, increases in lean subjects during local administration of isoprenaline, 13-15 terbutaline 13,16 or dobutamine. 13 However, little is known on whether badrenoceptor changes in local nutritive blood flow are altered in obesity.
The aim of the present study was to investigate subcutaneous adipose tissue lipolysis during local administration of b-agonists through a microdialysis probe to study whether the b-adrenergic sensitivity for lipolysis and the nutritive blood flow response were altered in obese males . At baseline, the ethanol out/in ratios tended to be higher in obese as compared to lean males, indicative of a blunted nutritive blood flow in the basal state in obese subjects. Basal interstitial glycerol concentrations were comparable in both groups. During the local administration of nonselective b-, b 1 -and b 2 -adrenoceptor agonists, interstitial glycerol concentrations increased and ethanol out/in ratios decreased similarly in obese and lean men. This suggests that obese and lean males have a comparable adipocyte b-adrenergic sensitivity and nutritive blood flow response.
Our data seem consistent with a previous microdialysis study, 20 which showed no difference in the increase in interstitial glycerol concentrations with in situ isoprenaline administration in lean and obese men. In contrast to our findings, it has been previously shown that obese women and obese female adolescents have an impaired increase in interstitial glycerol levels during local b 2 -adrenergic stimulation, 21 and that lipolytic sensitivity to norepinephrine was suppressed in abdominal subcutaneous fat cells from upper body obese women, ascribed to a 10-fold decrease in lipolytic b 2 -adrenoceptor sensitivity. 6 A possible explanation for this apparent discrepancy may be related to differences in gender. It has been shown that there may be differences in catecholamine-mediated lipolysis in subcutaneous adipose tissue between women and men with a higher lipolysis in women or a more pronounced difference in lipolysis between abdominal and gluteal adipocytes in women as compared to men. 22 Secondly, b-adrenergically mediated lipolysis may decrease with increasing age, 23, 24 but since in the above-indicated studies the study groups were matched for age this does not seem to contribute to the discrepant findings. Also, lipolytic and adipose tissue blood flow responses to epinephrine have been shown to be blunted in subcutaneous abdominal adipose tissue of upper body obese women as compared to lean women. 4 However, the difference in gender and differences in type of catecholamine used between the latter study and our study (ie the epinephrine effect may be because of variation in the functional balance between b-and a 2 -adrenoceptors) makes a comparison with our data difficult. From the present data, it can be speculated that the previously reported impaired whole-body lipolytic response in obese males after i.v. b-adrenoceptor agonist infusion might be explained by a blunted adipose tissue blood flow response rather than by a diminished b-adrenergic sensitivity of the fat cell or local adipose tissue nutritive blood flow effects. Indeed, adipose tissue blood flow, as measured by the 133 xenon-clearance technique, has been reported to be significantly lower in obese compared to lean subjects, both at rest [7] [8] [9] [10] [11] and during i.v. epinephrine 4, 12 and isoprenaline infusion. 8 An impaired subcutaneous abdominal adipose tissue blood flow response may affect the delivery of hormones and transport proteins for fatty acids to adipose tissue. Also, the release and reuptake of fatty acids within adipose tissue may be controlled by adipose tissue blood flow. The question remains whether the impaired whole- is a cause or a consequence of obesity. Studies from our group show that during i.v. badrenoceptor agonist administration, the increase in subcutaneous abdominal adipose tissue blood flow partially improves after weight reduction. 8 This suggests that a defective sympathetically mediated blood flow response may rather be a secondary factor resulting from the obese state than a primary factor leading to the development of obesity. In summary, nonselective b-, b 1 -and b 2 -adrenoceptormediated increases in interstitial glycerol concentration and local nutritive blood flow were similar in subcutaneous abdominal adipose tissue in obese and lean men. This suggests that the diminished whole-body b-adrenoceptormediated lipolytic response, as reported earlier by our group, 3, 5 is probably not for a large part explained by a blunted local adipocyte b-adrenergic sensitivity or nutritive blood flow. More likely, the impaired whole-body lipolytic response during i.v. b-adrenoceptor agonist administration is caused by a blunted adipose tissue blood flow response (as measured by 133 xenon wash-out), which results in an impaired agonist delivery and an impaired glycerol and NEFA release from the adipose tissue in obese male subjects.
